- Email: [email protected]
P184 Variations of lipids (L) and blood pressure (BP) during combined continuous hormone replacement therapy (CC-HRT) in postmenopausal women(PW)
P182 (cant)
P183 INFLUENCE ON LIPOPROTEIN AND BONE METABOLISM OF MEGESTROL ACETATE, USED IN THE MANAGEMENT OF SYMPTOMATIC POSTMENOPAUSAL WOMEN.
Both therapies resulted in a small fall in total cholesterol (pcO.05) with a significant fall in LDL (-16%, p
E Farish, K Ekevall, J F Barnes, CD Fletcher, D M Hart.
Departments of BiochemistryandGynaecology,Stobhill NHS Trust, Glasgow,UK The study aimedto assess the influenceon lipoprotein and bone metabolismof megestrolacetate(Megace),prescribedfor relief of vasomotorsymptomsto menopausalwomen with a history of oestrogen-dependent neoplasticdisease,extensiveendometriosis or thromboembolicphenomenafor whom oestrogentreatmentwas contraindicated. Sixty women were studied; 43 were on no concurrentmedicationand the remaining17 were on long-term tamoxifen therapy for breastcancer. Fastingserumlipoproteins were estimatedat 0,3 and 6 months. In the group treatedwith Megace alone there were significant decreasesin triglycerides (p
PM3 (cant)
P184 VARIATIONS OF LIPIDS (L) AND BLOOD PRESSURE(BP) DURING COMBINED CONTINUOUS HORMONE REPLACEMENT THERAPY (CC-HRT) IN POSTMENOPAUSAL WOMEN(PW).
There were significant decreases in alkaline phosphatase in both groups (p
M Martino, D Rodriguez Deza, A Mirkin.
Vidal, M Paciocco,
M Aguirre,
E Gil
Departmentsof Climateric& Gynecology. School of Medicine. Rosario.Argentina. The aim of this randomizedcrossoverstudy was to evaluatethe changesin serumlevels of cholesterol(Col), HDL cholesterol (HDL-C) and triglycerides(TGL). Assessment of cardiovascular risk index (CRI) and BP wasalsoperformedin PW treatedwith a CC-HRTregimenwith two different opposedprogestagen doses.63 PW agedbetween37-64years(mean53) werefollowedduring one year. All receivedtwo coursesof 6 monthstreatment,with one monthwash-outperiodbetweenthem. GroupA s33 received17Bestradiol(E2) (2mg/d) and medroxyprogesterone acetate(MAP) 5mg during the 1stcourse(Al) and MAP 2.5mgin the 2nd (A2). GroupB n=30 receivedthe samedosesof E2 andMAP 2.5mgand 5mgduring the 1st(Bl) and2nd (B2) courserespectively. Fasting serumCol, HDL-C andTGL levels;CRI andBP hadwereevaluated at baseline.6 monthsand12 monthsof the treatment.The statistical
Continued 174
P184 (cold)
P185 EFFECT OF PROGESTOGENS ON PLASMA LIPIDS AND LIPOPROTEINS IN POSTMENOPAUSAL WOMEN USING CONJUGATED ESTROGENS.
In both treatments the mean Col had a significant decrease. No differences were found between the two doses of MAP. TGL has a slight increase, however these levels decreased with the high doses (MAP 5mg). No differences were found in the others variables. The individual analysis of each group demonstrated the following differences: 1) In short-term the decrease of L values was MAP doses related. 2) In long-term, L values were more influenced by the time of HRT than, for the MAP doses delivered.
S Takada, T Teramoto *, T Morita, M Fukazawa, H Mori, Dept. Ob./Gyn., *Int.Med., Teikyo Univ. School of Med., Kaga 211-1, Itabashi-ku Tokyo 173, Japan. To examine the effect of progestogen has on changes in lipid and lipoprotein metabolism evoked by continuous estrogen replacement therapy, post menopausal women aged 42 to 64 years with serum FSH level >30 mIU/mL and serum E2 levels <40 pg/mL were enrolled to present study. Group A was consisted of fourteen women daily administrated 0.625 mg of conjugated estrogens (CE), and group B of twenty-eight women with additional daily 2.5 or 5 mg of methylmedroxyprogesteronacetate (MPA) for 12 weeks. Blood samples were obtained in the morning after overnight fasting. As 13 from 42 were excluded or dropped out, final cases of group A was 13 and group B was 11. High-density lipoprotein (HDL) cholesterol increased from baseline in both treatment groups (A;+21% vs B;+7%). Low-density lipoprotein(LDL) cholesterol decreased from baseline in both treatment groups (A:-16% vs B; 11%) which revealed no significant difference. MPA had no significant effects on the estrogen-induced increases in Apo-Al and triglycerides nor on the decreases in APO-B and LDL-cholesterol. We concluded that MPA did not eliminate the good influence on the metabolic effect of estrogen on lipids and lipoproteins.
P187
PM6 SERUM LIPID PROFILE OF SURGICAL AND NATURAL POSTMENOPAUSAL TURKISH WOMEN Soransav. 0. Giikmen, H.Celikkanat, B.Sener, G. &aksit, P. Miir6y Dr. Zekai Tahir Burak Women’s Hospital, Ankara, Turkey 219 surgical and 268 natural menopausal women were evaluated on their first visit to our menopausal clinic. Serum levels of cholesterol, triglyceride and other cholesterol fractions were significantly different in women with surgical menopause It is interesting to mention that the difference between two groups disappeared after three years of postmenopausal period while serum HDL-c the so called protective fraction levels of natural menopausal group always remained higher. On the other hand age matched comparison of serum lipid profiles between surgical and natural menopausal women give an important key that only the first group which contained 35-40 years of age showed a significant difference on triglycerides. Comparison of other age groups such as 41-45,4650 and 5 1-55 had no significant differences for each of the variables studied. It is concluded that the decrease of cardioprotective effect is even worse after surgical removal of bilateral ovaries.
175
THE EFFECTS OF HORMONE REPLACEMENT THERAPY ON SERUM CONCENTRATIONS OF LIPOPROTEIN (a), ANGIOTENSIN CONVERTING ENZYME AND INSULIN IN POSTMENOPAUSE NC Seckin, AB Sener*, No Turhan, 0 Gtikmen*, S &men, M &t&k, 0 Kaftanoglu The Turkish Health and Therapy Foundation Hospital Ciftlik Cad. No: 57 , 06510 Emek Ankara Turkey *Dr. Zekai Tahir Burak Womens’ Hospital HamamBnii Ankara Turkey Postmenopausal estrogen replacement therapy reduces the incidence and mortality due to cardiovascular disease. This cardioprotective effect may be at least partially explained by the favorable serum lipoprotein profile specifically the wellknown increase in high lipoprotein cholesterol seen in women taking postmenopausal estrogen. Direct effects on arterial blood flow has also been suggested to be involve and considerable work is currently being undertaken to determine other possible mechanisms. Elevated serum lipoprotein (a) and angiotensin-converting enzyme levels especially in postmenopause have been both suggested to be independent risk factors for atherogenesis. Insulin resistance and glucose intolerance also have been shown to be significant cardiovascular risk factors particularly in women. In a group of 150 healthy postmenopausal patients who had undergone natural or surgical menopause at least 6 months previously, lipoprotein (a), angiotensin-converting enzyme and insulin levels were studied before and after two years of hormone replacement therapy.
P183 INFLUENCE ON LIPOPROTEIN AND BONE METABOLISM OF MEGESTROL ACETATE, USED IN THE MANAGEMENT OF SYMPTOMATIC POSTMENOPAUSAL WOMEN.
Both therapies resulted in a small fall in total cholesterol (pcO.05) with a significant fall in LDL (-16%, p
E Farish, K Ekevall, J F Barnes, CD Fletcher, D M Hart.
Departments of BiochemistryandGynaecology,Stobhill NHS Trust, Glasgow,UK The study aimedto assess the influenceon lipoprotein and bone metabolismof megestrolacetate(Megace),prescribedfor relief of vasomotorsymptomsto menopausalwomen with a history of oestrogen-dependent neoplasticdisease,extensiveendometriosis or thromboembolicphenomenafor whom oestrogentreatmentwas contraindicated. Sixty women were studied; 43 were on no concurrentmedicationand the remaining17 were on long-term tamoxifen therapy for breastcancer. Fastingserumlipoproteins were estimatedat 0,3 and 6 months. In the group treatedwith Megace alone there were significant decreasesin triglycerides (p
PM3 (cant)
P184 VARIATIONS OF LIPIDS (L) AND BLOOD PRESSURE(BP) DURING COMBINED CONTINUOUS HORMONE REPLACEMENT THERAPY (CC-HRT) IN POSTMENOPAUSAL WOMEN(PW).
There were significant decreases in alkaline phosphatase in both groups (p
M Martino, D Rodriguez Deza, A Mirkin.
Vidal, M Paciocco,
M Aguirre,
E Gil
Departmentsof Climateric& Gynecology. School of Medicine. Rosario.Argentina. The aim of this randomizedcrossoverstudy was to evaluatethe changesin serumlevels of cholesterol(Col), HDL cholesterol (HDL-C) and triglycerides(TGL). Assessment of cardiovascular risk index (CRI) and BP wasalsoperformedin PW treatedwith a CC-HRTregimenwith two different opposedprogestagen doses.63 PW agedbetween37-64years(mean53) werefollowedduring one year. All receivedtwo coursesof 6 monthstreatment,with one monthwash-outperiodbetweenthem. GroupA s33 received17Bestradiol(E2) (2mg/d) and medroxyprogesterone acetate(MAP) 5mg during the 1stcourse(Al) and MAP 2.5mgin the 2nd (A2). GroupB n=30 receivedthe samedosesof E2 andMAP 2.5mgand 5mgduring the 1st(Bl) and2nd (B2) courserespectively. Fasting serumCol, HDL-C andTGL levels;CRI andBP hadwereevaluated at baseline.6 monthsand12 monthsof the treatment.The statistical
Continued 174
P184 (cold)
P185 EFFECT OF PROGESTOGENS ON PLASMA LIPIDS AND LIPOPROTEINS IN POSTMENOPAUSAL WOMEN USING CONJUGATED ESTROGENS.
In both treatments the mean Col had a significant decrease. No differences were found between the two doses of MAP. TGL has a slight increase, however these levels decreased with the high doses (MAP 5mg). No differences were found in the others variables. The individual analysis of each group demonstrated the following differences: 1) In short-term the decrease of L values was MAP doses related. 2) In long-term, L values were more influenced by the time of HRT than, for the MAP doses delivered.
S Takada, T Teramoto *, T Morita, M Fukazawa, H Mori, Dept. Ob./Gyn., *Int.Med., Teikyo Univ. School of Med., Kaga 211-1, Itabashi-ku Tokyo 173, Japan. To examine the effect of progestogen has on changes in lipid and lipoprotein metabolism evoked by continuous estrogen replacement therapy, post menopausal women aged 42 to 64 years with serum FSH level >30 mIU/mL and serum E2 levels <40 pg/mL were enrolled to present study. Group A was consisted of fourteen women daily administrated 0.625 mg of conjugated estrogens (CE), and group B of twenty-eight women with additional daily 2.5 or 5 mg of methylmedroxyprogesteronacetate (MPA) for 12 weeks. Blood samples were obtained in the morning after overnight fasting. As 13 from 42 were excluded or dropped out, final cases of group A was 13 and group B was 11. High-density lipoprotein (HDL) cholesterol increased from baseline in both treatment groups (A;+21% vs B;+7%). Low-density lipoprotein(LDL) cholesterol decreased from baseline in both treatment groups (A:-16% vs B; 11%) which revealed no significant difference. MPA had no significant effects on the estrogen-induced increases in Apo-Al and triglycerides nor on the decreases in APO-B and LDL-cholesterol. We concluded that MPA did not eliminate the good influence on the metabolic effect of estrogen on lipids and lipoproteins.
P187
PM6 SERUM LIPID PROFILE OF SURGICAL AND NATURAL POSTMENOPAUSAL TURKISH WOMEN Soransav. 0. Giikmen, H.Celikkanat, B.Sener, G. &aksit, P. Miir6y Dr. Zekai Tahir Burak Women’s Hospital, Ankara, Turkey 219 surgical and 268 natural menopausal women were evaluated on their first visit to our menopausal clinic. Serum levels of cholesterol, triglyceride and other cholesterol fractions were significantly different in women with surgical menopause It is interesting to mention that the difference between two groups disappeared after three years of postmenopausal period while serum HDL-c the so called protective fraction levels of natural menopausal group always remained higher. On the other hand age matched comparison of serum lipid profiles between surgical and natural menopausal women give an important key that only the first group which contained 35-40 years of age showed a significant difference on triglycerides. Comparison of other age groups such as 41-45,4650 and 5 1-55 had no significant differences for each of the variables studied. It is concluded that the decrease of cardioprotective effect is even worse after surgical removal of bilateral ovaries.
175
THE EFFECTS OF HORMONE REPLACEMENT THERAPY ON SERUM CONCENTRATIONS OF LIPOPROTEIN (a), ANGIOTENSIN CONVERTING ENZYME AND INSULIN IN POSTMENOPAUSE NC Seckin, AB Sener*, No Turhan, 0 Gtikmen*, S &men, M &t&k, 0 Kaftanoglu The Turkish Health and Therapy Foundation Hospital Ciftlik Cad. No: 57 , 06510 Emek Ankara Turkey *Dr. Zekai Tahir Burak Womens’ Hospital HamamBnii Ankara Turkey Postmenopausal estrogen replacement therapy reduces the incidence and mortality due to cardiovascular disease. This cardioprotective effect may be at least partially explained by the favorable serum lipoprotein profile specifically the wellknown increase in high lipoprotein cholesterol seen in women taking postmenopausal estrogen. Direct effects on arterial blood flow has also been suggested to be involve and considerable work is currently being undertaken to determine other possible mechanisms. Elevated serum lipoprotein (a) and angiotensin-converting enzyme levels especially in postmenopause have been both suggested to be independent risk factors for atherogenesis. Insulin resistance and glucose intolerance also have been shown to be significant cardiovascular risk factors particularly in women. In a group of 150 healthy postmenopausal patients who had undergone natural or surgical menopause at least 6 months previously, lipoprotein (a), angiotensin-converting enzyme and insulin levels were studied before and after two years of hormone replacement therapy.